Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: New-onset Type 1 Diabetes Mellitus Clear all
Not listed Phase 1Phase 2 Interventional

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

NCT01947569
View directory record Official record
Conditions
Treatment of Type I Diabetes Mellitus.
Interventions
Biological
Biological
Lead sponsor
DiaVacs, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Jun 10, 2026, 4:09 AM EDT
Recruiting Phase 2 Interventional

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

NCT07187531
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
High Dose SAB-142, Low Dose SAB-142, Placebo
Drug · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
5 Years to 40 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
23
States / cities
San Francisco, California • San Jose, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional Results available

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

NCT03895437
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
TOL-3021, TOL-3021 Placebo
Biological · Other
Lead sponsor
Tolerion, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
23
States / cities
San Diego, California • San Francisco, California • San Mateo, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

NCT02293837
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
Interventions
Tocilizumab (TCZ), Placebo, Standard of Care
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jun 10, 2026, 4:09 AM EDT
Not listed No phase listed Observational

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study

NCT06177691
View directory record Official record
Conditions
Type1 Diabetes
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Rituximab in New Onset Type 1 Diabetes

NCT00279305
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Anti-CD20 (rituximab), Placebo Comparator
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Jun 10, 2026, 4:09 AM EDT
Active, not recruiting Phase 2 Interventional

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

NCT03929601
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rituximab-pvvr, Abatacept, Sterile Sodium Chloride
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 10, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional Results available

Inducing Remission in Type 1 Diabetes With Alefacept

NCT00965458
View directory record Official record
Conditions
New-onset Type 1 Diabetes Mellitus
Interventions
Alefacept, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 35 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)

NCT02971202
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
Interventions
Hyperinsulinemic, euglycemic clamp, 20% dextrose
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years to 51 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Jun 10, 2026, 4:09 AM EDT
Withdrawn Phase 2 Interventional

Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)

NCT03794973
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
TOL-3021, TOL-3021 Placebo
Biological · Other
Lead sponsor
Tolerion, Inc.
Industry
Eligibility
12 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects

NCT00529399
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 45 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes

NCT03624062
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
MAS-1 adjuvanted Insulin B-chain
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

ATG-GCSF in New Onset Type 1 Diabetes

NCT02215200
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

NCT04270942
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
teplizumab 1 mg/mL
Drug
Lead sponsor
Provention Bio, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Proleukin and Rapamune in Type 1 Diabetes

NCT00525889
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
IL-2, Rapamycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
New York, New York • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)

NCT00529191
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes

NCT04233034
View directory record Official record
Conditions
Type1 Diabetes
Interventions
HCL, verapamil 120mg tablet, non-HCL, placebo
Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jun 10, 2026, 4:09 AM EDT
Active, not recruiting No phase listed Observational

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

NCT04598893
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Teplizumab, Placebo
Biological · Other
Lead sponsor
Provention Bio, a Sanofi Company
Industry
Eligibility
9 Years to 19 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Walnut Creek, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

NCT00129259
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
Biological · Other · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

New Onset Type 1 Diabetes: Role of Exenatide

NCT01269034
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exenatide, Rapid and long acting insulin, long acting insulin + rapid acting + 1.25 mcg Exenatide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Jun 10, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus

NCT00545857
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
pioglitazone, Placebo control
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Jun 10, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional Results available

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

NCT02093221
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
6 Years to 35 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jun 10, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

NCT04899271
View directory record Official record
Conditions
New-onset Type 1 Diabetes
Interventions
Ladarixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jun 10, 2026, 4:09 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

NCT05018585
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU, Placebo
Biological · Dietary Supplement
Lead sponsor
Diamyd Medical AB
Industry
Eligibility
12 Years to 28 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Newport Beach, California • Palo Alto, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 10, 2026, 4:09 AM EDT